Literature DB >> 2783402

Characterization of activated lymphocytes in colon cancer.

E C Ebert1, R E Brolin, A I Roberts.   

Abstract

The percentages of activated lymphocytes in colon cancers were compared to clinical features of the tumors and to functional characteristics of the tumor-infiltrating lymphocytes (TIL) in order to evaluate the role of activated TIL in controlling tumor growth. The TIL isolated from colon cancers contained 80 +/- 6% T cells [cluster designation (CD) 2+], 42 +/- 9% CD4+ cells, 27 +/- 9% CD8+ cells, 17 +/- 5% cells (surface immunoglobulin or SIg+), 6 +/- 2% null cells (CD2-, SIg-), 6 +/- 4% Leu 7+ cells, 1 +/- 0% macrophages (CDw 14+), and no plasma cells (PCA+). The lamina propria lymphocytes (LPL) isolated from adjacent colonic mucosa contained a similar distribution but with fewer CD8+ (10 +/- 5%) and Leu 7+ (0.6 +/- 0.3%) lymphocytes (P less than 0.05). More TIL than LPL expressed the interleukin-2 (IL-2) receptor (9 +/- 8% vs 1 +/- 0.8% CD25+ cells; P less than 0.05) and the transferrin receptor (4 +/- 5% vs 0.3 +/- 0.6% T9+ cells; P less than 0.05). Those TIL expressing activation antigens were CD2+, SIg-. The percentage of TIL that were CD25+ did not correlate with the extent of tumor spread, with the degree of tumor differentiation, nor with the percentage of HLA-DR+ tumor cells. However, there were significantly more CD25+ TIL from tumors located in the left colon, particularly small lesions, than from tumors located in the right colon (P less than 0.05). The proliferation of TIL preparations cultured with medium alone, with mitogens, or with IL-2 did not vary according to the percentage of CD25+ lymphocytes in the TIL. T cells may be activated by foreign surface determinants on tumor cells, particularly in small, left-sided lesions.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2783402     DOI: 10.1016/0090-1229(89)90223-7

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  12 in total

1.  IL-10 enhances IL-2-induced proliferation and cytotoxicity by human intestinal lymphocytes.

Authors:  E C Ebert
Journal:  Clin Exp Immunol       Date:  2000-03       Impact factor: 4.330

Review 2.  The colorectal cancer immune microenvironment and approach to immunotherapies.

Authors:  Minoru Koi; John M Carethers
Journal:  Future Oncol       Date:  2017-08-22       Impact factor: 3.404

3.  Lymphocytes infiltrating colorectal cancer have low proliferative capacity but can secrete normal levels of interferon gamma.

Authors:  W J Bateman; I Donnellan; I A Fraser; L S Wong; A G Morris
Journal:  Cancer Immunol Immunother       Date:  1995-07       Impact factor: 6.968

4.  T cell killing of human colon carcinomas by monoclonal-antibody-targeted superantigens.

Authors:  P A Lando; M Dohlsten; G Hedlund; E Akerblom; T Kalland
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

5.  Spontaneous cytotoxicity of intestinal intraepithelial lymphocytes: clues to the mechanism.

Authors:  A I Roberts; S M O'Connell; L Biancone; R E Brolin; E C Ebert
Journal:  Clin Exp Immunol       Date:  1993-12       Impact factor: 4.330

6.  Immunopathological features of human pulmonary tumors following low-dose interleukin-2.

Authors:  S G Swisher; T M Anderson; D R Wen; M A Stene; A J Cochran; S H Golub; E C Holmes
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

7.  Augmentation of interleukin-2-induced activation of human melanoma tumor-infiltrating lymphocytes by heteroconjugate antibody.

Authors:  P F Mansfield; M G Rosenblum; J L Murray; K Itoh
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

Review 8.  Studies using the anti-idiotypic monoclonal antibody 105AD7 in patients with primary and advanced colorectal cancer.

Authors:  Charles Maxwell-Armstrong
Journal:  Ann R Coll Surg Engl       Date:  2002-09       Impact factor: 1.891

9.  Lymphocyte recruitment into the tumor site is altered in patients with MSI-H colon cancer.

Authors:  Kristen M Drescher; Poonam Sharma; Patrice Watson; Zoran Gatalica; Stephen N Thibodeau; Henry T Lynch
Journal:  Fam Cancer       Date:  2009-01-23       Impact factor: 2.375

10.  Clonal and functional analysis for the augmentation of tumour-infiltrating lymphocytes by interleukin 4.

Authors:  T Tsunoda; H Tanimura; H Yamaue; M Iwahashi; M Tani; K Noguchi; T Hotta; S Mizobata; K Arii
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.